Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

Background Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for
medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or …

Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific
stressors, occupies a central position in the development of novel anticancer treatments …

Abstract The “hotness” or “coldness” of the tumors are determined by the information of the
cancer cells themselves, tumor immune characteristics, tumor microenvironment, and …

Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through
accurate assessment of minimal residual disease (MRD) and therapeutic response …